Trial Search Results

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   - Planned or completed first allogeneic stem cell transplant (any conditioning regimen,
   graft source, donor type and GVHD prophylaxis regimen)

   - Signed, informed consent and, if applicable, child assent

Exclusion Criteria:

   - Inability to comply with study procedures

   - Anticipated survival less than 6 months due to co-morbid disease

   - Autoimmune disorder or inherited immunodeficiency before HCT

   - Diagnosis of late acute or chronic GVHD prior to study enrollment

   - Hematologic relapse or chemotherapy refractory disease at restaging within 1 month of
   HCT or at the time of enrollment (e.g., > 5% blasts for leukemia; poorly responsive
   lymphoma)

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Physician Referrals
650-723-0822
Not Recruiting